You are here
Clinical Trial To Evaluated Telcyta as Front-Line Treatment of Non-Small Cell Lung Cancer Initiated
PALO ALTO, Calif., March 9 /PRNewswire-FirstCall/ -- Telik, Inc. announced the initiation of a multicenter Phase 1-2a clinical trial in which TELCYTA™ (TLK286) will be evaluated in combination with cisplatin in the front-line treatment of Stage IIIb or IV non-small cell lung cancer (NSCLC). The trial is expected to enroll approximately 50 NSCLC patients who have not previously received chemotherapy. Platinum is the current mainstay of front-line metastatic lung cancer treatment.
The trial is based upon the clinical results reported at the AACR-NCI-EORTC meeting in November 2003 in which TELCYTA demonstrated the ability to contribute to platinum-based chemotherapy without unanticipated toxicities.
About Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer deaths in men and women in the United States, according to the American Cancer Society (ACS). The ACS estimates that more than 173,000 new cases of lung cancer will be diagnosed in 2004 and an estimated 160,400 deaths will result from the disease, representing approximately 28% of all cancer deaths in the U.S.
About TELCYTA™ and TELCYTA™ Clinical Trials
A Phase 3 registration trial is ongoing using TELCYTA™ as a single agent in the treatment of ovarian cancer, and a Phase 3 registration trial is expected to begin in the near future in the treatment of NSCLC. For further information on TELCYTA™ trials, visit http://www.telik.com/NewFiles/clinical_trials.html
TELCYTA™ is a small molecule tumor-activated drug which is activated by an enzyme present in higher levels in many human cancers than in normal tissues. Upon activation, an intracellular process known as apoptosis, or programmed cell death, is initiated. TELCYTA™, which has been evaluated in clinical trials in ovarian, NSCLC, breast and colorectal cancer, was discovered through the application of Telik's proprietary drug discovery technology, TRAP.
Source: Telik, Inc.